Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07417995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis

Study acronym: STRIDE-PsA
StatusNot Yet Recruiting
PhaseNot specified
Started2026-06
View on ClinicalTrials.gov ↗

Amendment history

2026-05-12
Study Status v2
Primary completion pushed: 2026-03 → 2027-06
Completion pushed: 2026-03 → 2027-06
Start date2026-03→2026-06
2026-02-19
Study Status, Study Description, Outcome Measures v1
Secondary endpointsdetails revised at 1 of 8 entries
Study description+45 characters
[...] mates of the minimally clinically important difference, and wethe investigators assume SD = 12.36 for the 12-week change from published dat [...] and to support regression analyses of treatment sequencing, wethe investigators plan to over-recruit, aiming for approximately 100 patients [...] ients have been commenced on b/tsDMARD therapy over a year, wethe investigators anticipate that recruitment from ten sites with a 50% conse [...]
2026-02-11
Original filing
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care. The main questions are: * Do treatment responses differ according to the number of previous advanced therapies? * Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness? Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development. Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.
Trial Details
NCT Number NCT07417995
Lead Sponsor Royal United Hospitals Bath NHS Foundation Trust
Collaborators: University of Bath
Conditions Psoriasis Arthritis
Enrollment 400 participants
Start Date 2026-06
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-13